Acriptega

45.00

Acriptega for HIV treatment Acriptega  includes Dolutegravir/Lamivudine/Tenofovir is a fixed-dose combination medication used for the treatment of HIV (Human Immunodeficiency Virus) infection. It is also known by its brand name Tivicay®, Lamivir®,  Tenof®. This combination drug contains three active ingredients: Dolutegravir: Dolutegravir is an integrase strand transfer inhibitor (INSTI) antiretroviral drug. It works by blocking…

Category:
Tags:

Description

Acriptega for HIV treatment

Acriptega  includes Dolutegravir/Lamivudine/Tenofovir is a fixed-dose combination medication used for the treatment of HIV (Human Immunodeficiency Virus) infection. It is also known by its brand name Tivicay®, Lamivir®,  Tenof®. This combination drug contains three active ingredients:

  1. Dolutegravir: Dolutegravir is an integrase strand transfer inhibitor (INSTI) antiretroviral drug. It works by blocking the integrase enzyme, which is essential for the replication of the HIV virus. By inhibiting this enzyme, dolutegravir helps to prevent the integration of the viral genetic material into the host cell’s DNA, effectively reducing the viral load and slowing down the progression of the disease.
  2. Lamivudine: Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) antiretroviral drug. It inhibits the reverse transcriptase enzyme, which is necessary for HIV replication. Lamivudine is often used in combination with other antiretroviral medications to suppress viral replication and reduce the viral load in the body.
  3. Tenofovir disoproxil fumarate (TDF): Tenofovir disoproxil fumarate is another nucleoside reverse transcriptase inhibitor (NRTI) antiretroviral drug. Like lamivudine, TDF also inhibits the reverse transcriptase enzyme, thus interfering with HIV replication.

The combination of Dolutegravir/Lamivudine/Tenofovir provides a complete antiretroviral regimen in a single pill, making it easier for patients to adhere to their treatment schedule. It is indicated for the treatment of HIV-1 infection in adults who have not previously received antiretroviral therapy or in those who are virologically suppressed and wish to switch to a new regimen.

As with any HIV treatment, the decision to use Acriptega (Dolutegravir/Lamivudine/Tenofovir) or any other antiretroviral medication should be made by a qualified healthcare professional based on an individual’s medical history, viral resistance testing, and treatment goals. Regular monitoring of viral load and CD4 cell counts is essential to assess the effectiveness of the medication and overall HIV management.